Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study brings lung rehab to africa: can exercise programs help millions?

NCT ID NCT07602673

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a supervised exercise and education program (pulmonary rehabilitation) can help people with long-term lung diseases like COPD, asthma, and post-TB lung damage in Nigeria, South Africa, and Cameroon. Researchers will enroll 90 patients to see if the program improves their ability to walk and their quality of life. The goal is to find out if this type of care can work in low-resource settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female adults (\>= 18 years) with specified clinical diagnosis (typically by detailed clinical history \[persistent symptoms for ≥6 months\] plus spirometry and/or other available tests, e.g., chest X-ray\] * Individuals with CRDs, specifically COPD, asthma or post-tuberculosis lung disorder * Patients with CRDs who have an indication for PR (specifically, these are patients with moderate to severe staged disease who present with reduced exercise/functional capacity, poor quality of life, high disease symptoms, particularly dyspnea) and are medically fit to undergo exercise training (which is to be determined by pre-exercise screening and field tests). * Patients with CRDs attending regular follow-up in the respiratory clinics of the selected centres. * Patients who are willing and able to provide written or oral (audio recorded) informed consent * All levels (primary, secondary, and tertiary) of healthcare professionals, including doctors, nurses, physiotherapists, respiratory therapists, medical assistants, healthcare administrators, pulmonologists, and other formal practitioners working in primary, secondary, and tertiary care settings, who provide services to patients who may potentially require PR. * Relevant stakeholders, including policymakers, religious leaders, sports leaders, the pharmaceutical industry, social workers, managers, and hospital/practice owners. * Willing and able to provide written or oral (audio recorded) informed consent. Exclusion Criteria: * Patients with other significant chronic co-morbidities such as heart failure, ischemic heart disease, DM, and confusion/dementia * Pregnant women * Co-morbidity that is a contraindication to PR (e.g., unstable angina, aortic aneurysm, recent myocardial infarction, acute infection, etc.) * Significant cognitive or physical impairment preventing participation in PR * Active pulmonary tuberculosis vi. Patient with current or recent disease exacerbations * Non-respiratory cause for symptoms (e.g., breathlessness due to heart failure, anaemia) * Unable to participate in exercise (e.g., due to severe arthritis or paralysis) * Undertaken PR within one year. * Unwilling to participate in the study. * Unable to give written or oral (audio recorded) informed consent * Healthcare professionals who are not involved in the care of patients who require PR, e.g., midwives * Having a conflict of interest that may influence the outcome * Unable and unwilling to give written or oral (audio recorded) informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic respiratory conditions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chris Hani Baragwanath Academic Hospital

    Johannesburg, Gauteng, 2041, South Africa

  • Lagos State University Hospital

    Lagos, Lagos, 00234, Nigeria

  • Regional Hospital Limbe

    Yaoundé, Cameroon

More trials for these conditions

Other studies related to the condition(s) this trial covers.